For pot stock investors, the first half of 2018 stank.
It was choppy – to say the least – thanks in no small part to meddling from U.S. Attorney General Jeff Sessions.
But I kept telling you to keep the faith – that a number of catalysts were lining up that would once again send legal marijuana stocks into the stratosphere.
I was right – and those of you who listened can feel a bit smug.
While other investors are scrambling to get back into legal cannabis, you're watching your holdings grow... and grow.
We can date cannabis' latest surge to Aug. 15. That was the day Constellation Brands Inc. (NYSE: STZ), the beverage giant behind Corona beer and Robert Mondavi wines, announced its plan to spend $3.8 billion to increase its stake in Canopy Growth Corp. (Nasdaq: CGC) to 38%.
In other words, a mainstream corporation had weighed the risks – and marched forward with a plan to dive into the marijuana industry... to the tune of billions of dollars.
The news sent marijuana stocks soaring.
This one stat shows it all: The bellwether North American Marijuana Index has climbed more than 175% since lows reached on Sept. 7, 2017.
And this is just the start...
In today's report, I'll tell you why that's so.
Plus, I'll reveal the latest Big Alcohol company to come sniffing around the cannabis industry.
And I'll help you find four pot stocks with triple-digit potential to buy now.
Before the next catalyst hits.
Take a look...
This Bud's for You
Anheuser-Busch InBev NV (NYSE: BUD) is the latest beverage giant to take a look at the industry.
AB InBev just appointed a "Chief Non-Alcohol Beverages Officer" to help it expand the company's nonalcoholic (including cannabis-based drinks) division, which it expects will rake in about 20% of its overall sales by 2025.
This doesn't mean you're going to be sipping a cannabis-infused Budweiser anytime soon. At least not in the United States, not while marijuana is illegal at the federal level.
But it does mean this $150.39 billion company is looking more closely at how they may profit from legal weed. Once marijuana is legalized (or at least further decriminalized) on the national level, weed-infused beverages could rake in U.S. sales of $15 billion a year, Fortune estimates.
We've been talking here about the profit potential behind cannabis for about two years now – and profiting hugely – so this news comes as no surprise to us.
Shares in one Canadian firm in our Nova-X Marijuana Millions model portfolio have climbed 41.6% since Aug. 15. Another Canadian company's shares have climbed nearly 67% since June 21 when I entered it in our Radical Technology Profits cannabis portfolio.
In other words, mainstream investors are starting to see what we've known for a while – and what AB InBev and Constellation are acting on.
And they're far from the only beverage behemoths looking to boost profits by diving into the legal cannabis industry.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.